This research identifies NME3 as a target for restoring mitochondrial balance in Parkinson's Disease, highlighting potential therapies.
NME3 is a previously unrecognized regulator of mitochondrial dynamics and a critical contributor to PD pathogenesis. Restoring mitochondrial fission-fusion balance through genetic or pharmacological approaches provides neuroprotection, highlighting NME3 as a promising target for disease-modifying PD therapies.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: